IPSCs, aging and age-related diseases

New Biotechnology

Volumn 31, Issue 5, 2014, Pages 411-421

  Isobe, Ken ichi ^a   Cheng, Zhao ^a   Nishio, Naomi ^a   Suganya, Thanasegan ^a   Tanaka, Yuriko ^a   Ito, Sachiko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALS; NEURODEGENERATIVE DISEASES; CYTOLOGY; DISEASE CONTROL; DISEASES; STEM CELLS;

AGE-RELATED DISEASE; ALZHEIMER'S DISEASE; COPY NUMBER VARIATIONS; EMBRYONIC STEM CELLS; PARKINSON'S DISEASE; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

STEM CELLS; CELLS;

BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN; PROTEIN P16; PROTEIN P53; SENESCENCE ASSOCIATED HETEROCHROMATIN FOCI; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; LEUKEMIA INHIBITORY FACTOR; LIF PROTEIN, HUMAN;

AGING; ALZHEIMER DISEASE; ANIMAL CELL; ATHEROSCLEROSIS; CARCINOGENICITY; CELL CULTURE; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL NUCLEUS TRANSPLANTATION; COPY NUMBER VARIATION; DEMETHYLATION; DIABETES MELLITUS; DNA METHYLATION; EMBRYONIC STEM CELL; END STAGE RENAL DISEASE; EPIGENETICS; FERTILIZATION; FIBROBLAST; GERM LAYER; HISTOCOMPATIBILITY; HISTONE MODIFICATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; INNER CELL MASS; MACROPHAGE; NONHUMAN; OOCYTE; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROMOTER REGION; REGENERATIVE MEDICINE; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; SOMATIC CELL; TELOMERE SHORTENING; TERATOMA; ADULT; ANIMAL; CELL AGING; DRUG EFFECTS; METABOLISM; MOUSE; PATHOLOGY; PROCEDURES; STEM CELL TRANSPLANTATION; TRANSPLANTATION; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEVELOPMENTAL BIOLOGY; GERIATRIC DISORDER; KIDNEY FAILURE; LIVER CIRRHOSIS; OSTEOARTHRITIS; OSTEOPOROSIS;

ADULT; AGING; ANIMALS; CELL AGING; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LEUKEMIA INHIBITORY FACTOR; MICE; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

MURINAE; MUS;

EID: 84902014346     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2014.04.004     Document Type: Review

References (104)

1. Robinton D.A., Daley G.Q. The promise of induced pluripotent stem cells in research and therapy. Nature 2012, 481:295-305.
2. Papp B., Plath K. Epigenetics of reprogramming to induced pluripotency. Cell 2013, 152:1324-1343.
3. Carpenter M.K., Frey-Vasconcells J., Rao M.S. Developing safe therapies from human pluripotent stem cells. Nat Biotechnol 2009, 27:606-613.
4. Daley G.Q. Cellular alchemy and the golden age of reprogramming. Cell 2012, 151:1151-1154.
5. Evans M.J., Kaufman M.H. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981, 292:154-156.
6. Martin G.R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A 1981, 78:7634-7638.
7. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
8. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146.
9. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
10. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
11. Gardner R.L. Mouse chimeras obtained by the injection of cells into the blastocyst. Nature 1968, 220:596-597.
12. Brinster R.L. Hexokinase activity in the preimplantation mouse embryo. Enzymologia 1968, 34:304-308.
13. Briggs R., King T.J. Transplantation of living nuclei from blastula cells into enucleated frogs' eggs. Proc Natl Acad Sci U S A 1952, 38:455-463.
14. Gurdon J.B. Adult frogs derived from the nuclei of single somatic cells. Dev Biol 1962, 4:256-273.
15. Campbell K.H., McWhir J., Ritchie W.A., Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. Nature 1996, 380:64-66.
16. Wakayama T., Perry A.C., Zuccotti M., Johnson K.R., Yanagimachi R. Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei. Nature 1998, 394:369-374.
17. Feng S., Jacobsen S.E., Reik W. Epigenetic reprogramming in plant and animal development. Science 2010, 330:622-627.
18. Meissner A. Epigenetic modifications in pluripotent and differentiated cells. Nat Biotechnol 2010, 28:1079-1088.
19. Hanna J., Saha K., Pando B., van Zon J., Lengner C.J., Creyghton M.P., et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 2009, 462:595-601.
20. Cheng Z., Ito S., Nishio N., Xiao H., Zhang R., Suzuki H., et al. Establishment of induced pluripotent stem cells from aged mice using bone marrow-derived myeloid cells. J Mol Cell Biol 2011, 3:91-98.
21. Polo J.M., Anderssen E., Walsh R.M., Schwarz B.A., Nefzger C.M., Lim S.M., et al. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell 2012, 151:1617-1632.
22. Samavarchi-Tehrani P., Golipour A., David L., Sung H.K., Beyer T.A., Datti A., et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010, 7:64-77.
23. Haigis M.C., Yankner B.A. The aging stress response. Mol Cell 2010, 40:333-344.
24. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005, 6:611-622.
25. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965, 37:614-636.
26. Itahana K., Campisi J., Dimri G.P. Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. Methods Mol Biol 2007, 371:21-31.
27. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005, 120:513-522.
28. Cheng Z., Ito S., Nishio N., Thanasegaran S., Fang H., Isobe K. Characteristics of cardiac aging in C57BL/6 mice. Exp Gerontol 2013, 48:341-348.
29. Adler A.S., Sinha S., Kawahara T.L., Zhang J.Y., Segal E., Chang H.Y. Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev 2007, 21:3244-3257.
30. Hardy K., Mansfield L., Mackay A., Benvenuti S., Ismail S., Arora P., et al. Transcriptional networks and cellular senescence in human mammary fibroblasts. Mol Biol Cell 2005, 16:943-953.
31. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev 2004, 18:2195-2224.
32. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
33. Yagi T., Kosakai A., Ito D., Okada Y., Akamatsu W., Nihei Y., et al. Establishment of induced pluripotent stem cells from centenarians for neurodegenerative disease research. PLoS ONE 2012, 7:e41572.
34. Prigione A., Hossini A.M., Lichtner B., Serin A., Fauler B., Megges M., et al. Mitochondrial-associated cell death mechanisms are reset to an embryonic-like state in aged donor-derived iPS cells harboring chromosomal aberrations. PLoS ONE 2011, 6:e27352.
35. Qiu X., Yang J., Liu T., Jiang Y., Le Q., Lu Y. Efficient generation of lens progenitor cells from cataract patient-specific induced pluripotent stem cells. PLoS ONE 2012, 7:e32612.
36. Wen Y., Wani P., Zhou L., Baer T., Phadnis S.M., Reijo Pera R.A., et al. Reprogramming of fibroblasts from older women with pelvic floor disorders alters cellular behavior associated with donor age. Stem Cells Transl Med 2013, 2:118-128.
37. Lapasset L., Milhavet O., Prieur A., Besnard E., Babled A., Aït-Hamou N., et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev 2011, 25:2248-2253.
38. Pawlikowska L., Hu D., Huntsman S., Sung A., Chu C., Chen J., et al. Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell 2009, 8:460-472.
39. Kenyon C.J. The genetics of ageing. Nature 2010, 464:504-512.
40. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
41. Chen T., Shen L., Yu J., Wan H., Guo A., Chen J., et al. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell 2011, 10:908-911.
42. Kudlow B.A., Kennedy B.K., Monnat R.J. Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat Rev Mol Cell Biol 2007, 8:394-404.
43. Bertola D.R., Cao H., Albano L.M., Oliveira D.P., Kok F., Marques-Dias M.J., et al. Cockayne syndrome type A: novel mutations in eight typical patients. J Hum Genet 2006, 51:701-705.
44. Andrade L.N., Nathanson J.L., Yeo G.W., Menck C.F., Muotri A.R. Evidence for premature aging due to oxidative stress in iPSCs from Cockayne syndrome. Hum Mol Genet 2012, 21:3825-3834.
45. Liu G.H., Barkho B.Z., Ruiz S., Diep D., Qu J., Yang S.L., et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 2011, 472:221-225.
46. Laurent L.C., Ulitsky I., Slavin I., Tran H., Schork A., Morey R., et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011, 8:106-118.
47. Gore A., Li Z., Fung H.L., Young J.E., Agarwal S., Antosiewicz-Bourget J., et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011, 471:63-67.
48. Hussein S.M., Batada N.N., Vuoristo S., Ching R.W., Autio R., Närvä E., et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011, 471:58-62.
49. Mayshar Y., Ben-David U., Lavon N., Biancotti J.C., Yakir B., Clark A.T., et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010, 7:521-531.
50. Abyzov A., Mariani J., Palejev D., Zhang Y., Haney M.S., Tomasini L., et al. Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature 2012, 492:438-442.
51. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
52. Gropp M., Shilo V., Vainer G., Gov M., Gil Y., Khaner H., et al. Standardization of the teratoma assay for analysis of pluripotency of human ES cells and biosafety of their differentiated progeny. PLoS ONE 2012, 7:e45532.
53. Shih C.C., Forman S.J., Chu P., Slovak M. Human embryonic stem cells are prone to generate primitive, undifferentiated tumors in engrafted human fetal tissues in severe combined immunodeficient mice. Stem Cells Dev 2007, 16:893-902.
54. Ben-David U., Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011, 11:268-277.
55. Ruggero D. Translational control in cancer etiology. Cold Spring Harb Perspect Biol 2013, 5.
56. Meyer N., Penn L.Z. Reflecting on 25 years with MYC. Nat Rev Cancer 2008, 8:976-990.
57. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
58. Wernig M., Meissner A., Cassady J.P., Jaenisch R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2008, 2:10-12.
59. Nakagawa M., Koyanagi M., Tanabe K., Takahashi K., Ichisaka T., Aoi T., et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008, 26:101-106.
60. Nakagawa M., Takizawa N., Narita M., Ichisaka T., Yamanaka S. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci U S A 2010, 107:14152-14157.
61. Stadtfeld M., Nagaya M., Utikal J., Weir G., Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008, 322:945-949.
62. Seki T., Yuasa S., Oda M., Egashira T., Yae K., Kusumoto D., et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010, 7:11-14.
63. Zhou W., Freed C.R. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 2009, 27:2667-2674.
64. Okita K., Hong H., Takahashi K., Yamanaka S. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc 2010, 5:418-428.
65. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322:949-953.
66. Kaji K., Norrby K., Paca A., Mileikovsky M., Mohseni P., Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009, 458:771-775.
67. Woltjen K., Michael I.P., Mohseni P., Desai R., Mileikovsky M., Hämäläinen R., et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009, 458:766-770.
68. Jia F., Wilson K.D., Sun N., Gupta D.M., Huang M., Li Z., et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods 2010, 7:197-199.
69. Yu J., Hu K., Smuga-Otto K., Tian S., Stewart R., Slukvin I.I., et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009, 324:797-801.
70. Kim D., Kim C.H., Moon J.I., Chung Y.G., Chang M.Y., Han B.S., et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4:472-476.
71. Zhou H., Wu S., Joo J.Y., Zhu S., Han D.W., Lin T., et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009, 4:381-384.
72. Warren L., Manos P.D., Ahfeldt T., Loh Y.H., Li H., Lau F., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630.
73. Yakubov E., Rechavi G., Rozenblatt S., Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys Res Commun 2010, 394:189-193.
74. Anokye-Danso F., Trivedi C.M., Juhr D., Gupta M., Cui Z., Tian Y., et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011, 8:376-388.
75. Miyoshi N., Ishii H., Nagano H., Haraguchi N., Dewi D.L., Kano Y., et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011, 8:633-638.
76. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
77. Thanasegaran S., Cheng Z., Ito S., Nishio N., Isobe K. No immunogenicity of IPS cells in syngeneic host studied by in vivo injection and 3D scaffold experiments. Biomed Res Int 2013, 2013:378207.
78. Araki R., Uda M., Hoki Y., Sunayama M., Nakamura M., Ando S., et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013, 494:100-104.
79. Guha P., Morgan J.W., Mostoslavsky G., Rodrigues N.P., Boyd A.S. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 2013, 12:407-412.
80. Okawa T., Kamiya H., Himeno T., Kato J., Seino Y., Fujiya A., et al. Transplantation of neural crest like cells derived from induced pluripotent stem cells improves diabetic polyneuropathy in mice. Cell Transplant 2013, 22:1763-1783.
81. Suzuki H., Shibata R., Kito T., Ishii M., Li P., Yoshikai T., et al. Therapeutic angiogenesis by transplantation of induced pluripotent stem cell-derived Flk-1 positive cells. BMC Cell Biol 2010, 11:72.
82. Inami Y., Yoshikai T., Ito S., Nishio N., Suzuki H., Sakurai H., et al. Differentiation of induced pluripotent stem cells to thymic epithelial cells by phenotype. Immunol Cell Biol 2011, 89:314-321.
83. Wernig M., Zhao J.P., Pruszak J., Hedlund E., Fu D., Soldner F., et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008, 105:5856-5861.
84. Byers B., Cord B., Nguyen H.N., Schüle B., Fenno L., Lee P.C., et al. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS ONE 2011, 6:e26159.
85. Soldner F., Laganière J., Cheng A.W., Hockemeyer D., Gao Q., Alagappan R., et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011, 146:318-331.
86. Soldner F., Hockemeyer D., Beard C., Gao Q., Bell G.W., Cook E.G., et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136:964-977.
87. Tanzi R.E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555.
88. Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012, 482:216-220.
89. Jang J., Yoo J.E., Lee J.A., Lee D.R., Kim J.Y., Huh Y.J., et al. Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery. Exp Mol Med 2012, 44:202-213.
90. Rashid S.T., Corbineau S., Hannan N., Marciniak S.J., Miranda E., Alexander G., et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010, 120:3127-3136.
91. Agarwal S., Holton K.L., Lanza R. Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells 2008, 26:1117-1127.
92. Song Z., Cai J., Liu Y., Zhao D., Yong J., Duo S., et al. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res 2009, 19:1233-1242.
93. Sullivan G.J., Hay D.C., Park I.H., Fletcher J., Hannoun Z., Payne C.M., et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 2010, 51:329-335.
94. Liu H., Kim Y., Sharkis S., Marchionni L., Jang Y.Y. In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med 2011, 3:82ra39.
95. Choi S.M., Kim Y., Liu H., Chaudhari P., Ye Z., Jang Y.Y. Liver engraftment potential of hepatic cells derived from patient-specific induced pluripotent stem cells. Cell Cycle 2011, 10:2423-2427.
96. Morizane R., Monkawa T., Itoh H. Differentiation of murine embryonic stem and induced pluripotent stem cells to renal lineage in vitro. Biochem Biophys Res Commun 2009, 390:1334-1339.
97. Song B., Smink A.M., Jones C.V., Callaghan J.M., Firth S.D., Bernard C.A., et al. The directed differentiation of human iPS cells into kidney podocytes. PLoS ONE 2012, 7:e46453.
98. Song J.J., Guyette J.P., Gilpin S.E., Gonzalez G., Vacanti J.P., Ott H.C. Regeneration and experimental orthotopic transplantation of a bioengineered kidney. Nat Med 2013, 19:646-651.
99. Nichols J.E., Niles J., Riddle M., Vargas G., Schilagard T., Ma L., et al. Production and assessment of decellularized pig and human lung scaffolds. Tissue Eng Part A 2013, 19:2045-2062.
100. Wang B., Miyagoe-Suzuki Y., Yada E., Ito N., Nishiyama T., Nakamura M., et al. Reprogramming efficiency and quality of induced Pluripotent Stem Cells (iPSCs) generated from muscle-derived fibroblasts of mdx mice at different ages. PLoS Curr 2011, 3:RRN1274.
101. Boulting G.L., Kiskinis E., Croft G.F., Amoroso M.W., Oakley D.H., Wainger B.J., et al. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol 2011, 29:279-286.
102. Feng Q., Lu S.J., Klimanskaya I., Gomes I., Kim D., Chung Y., et al. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells 2010, 28:704-712.
103. Gokoh M., Nishio M., Nakamura N., Matsuyama S., Nakahara M., Suzuki S., et al. Early senescence is not an inevitable fate of human-induced pluripotent stem-derived cells. Cell Reprogram 2011, 13:361-370.
104. He M., Callanan A. Comparison of methods for whole organ decellularization in tissue engineering of bioartificial organs. Tissue Eng Part B Rev 2013, 19:194-220.